Remifentanil reduces the release of biochemical markers of myocardial damage in patients undergoing on pump coronary artery bypass surgery by Wong, GTC et al.
Title
Remifentanil reduces the release of biochemical markers of
myocardial damage in patients undergoing on pump coronary
artery bypass surgery
Author(s) Wong, GTC; Huang, Z; Irwin, MG
Citation
The 2009 Annual Scientific Meeting of the Australian and New
Zealand College of Anaesthetists (ANZCA), Cairns, QLD.,
Australia, 2-6 May 2009.
Issued Date 2009
URL http://hdl.handle.net/10722/63439
Rights
© 2009. This manuscript version is made available under the CC-
BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-
nc-nd/4.0/; This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International
License.
RUSH: Journal of Cardiothoracic and Vascular Anesthesia article for proofing (# 1614)
 
_______________________
 
Dear Author
 
The proof of your article, to be published by Elsevier in the Journal of Cardiothoracic and Vascular
Anesthesia, is available as a "PDF" file at the following URL:
http://rapidproof.cadmus.com/RapidProof/retrieval/index.jsp
 
Login: your e-mail address
Password: 77Qx8tcZsM77
 
Also attached are instructions on the annotation of PDF files. You may also have a 'Query Form' as an
attachment if we have any questions regarding your article.
 
Please note that proof corrections can now be annotated on-screen, which allows you to mark directly in the
PDF file, and return the marked file as an e-mail attachment. To take advantage of this method, please
download the free Adobe Reader version 7 (or higher; see the attached instructions).
 
Alternative methods of returning proof corrections:
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the
Query Form) in an e-mail and return to us using the 'reply' button to this e-mail. Please list your corrections
quoting line number.
 
If, for any reason, this is not possible, mark the corrections and any other comments (including replies to the
Query Form) on a printout of your proof and fax this to the number given below, or scan the pages and e-
mail, or mail to the address given below.
 
Please use this proof for checking the typesetting, editing, completeness and correctness of the text, tables
and figures. Please ensure that you answer any questions (see the Query Form) that have arisen during the
preparation of your proof. Significant changes to the article as accepted for publication will only be
considered at this stage with permission from the Editor. We will do everything possible to get your article
published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent
back to us in one communication: please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed.
 
If you submitted usable colour figures with your article they will appear in colour on the web, at no extra
charge, as you can see in the attached PDF proof of your article. In the printed issue, colour reproduction
depends on journal policy and whether or not you agree to bear any costs (not applicable to journals which
appear only online). Any 'supplementary' material to your article (i.e., not appearing in print) will be
accessible after your corrected article is placed online; such material is not part of the proofing procedure
and is therefore not attached here.
 
Please respond promptly (even if you have no corrections): the sooner we hear from you, the sooner your
corrected article will appear online. Note that we may proceed with publication of your article if no response
is received.
 
Kind regards,
 
Nick DeAngelis
Issue Manager, YJCAN
Journal of Cardiothoracic and Vascular Anesthesia
Copy of e-mail Notification zl02542
Cadmus
300 West Chestnut Street
Ephrata, PA  17522
Ph: 717 721-2603, Fx: 717-738-9479 or 717-738-9478
E-mail: deangelisn@cadmus.com
P-annotatePDF-v7
INSTRUCTIONS ON THE ANNOTATION OF PDF FILES 
PDF files are self-contained documents for viewing on screen and for printing. They contain all appropriate
formatting and all fonts, so that the correct result will be shown on screen and on the printout from your local printer.
To view, print and annotate your article you will need Adobe Reader version 7 (or higher). This program is freely
available for a whole series of platforms that include PC, Mac, and UNIX and can be downloaded from
http://www.adobe.com/products/acrobat/readstep2.html. The exact system requirements are given at the Adobe site:
http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.
PDF ANNOTATIONS (for this you will need Adobe Reader version 7 or higher)
To make annotations in the PDF file, go to the main Adobe toolbar and change the cursor from a hand symbol to the
normal cursor by clicking on the ‘Select’ button  in the menu bar at the top. When you open the PDF file 
using Adobe Reader, the Commenting toolbar should be displayed automatically; if not, click on ‘Tools’, select
‘Commenting’ (or ‘Comment & Markup’), then click on ‘Commenting toolbar’ (or Show Comment & Markup
toolbar in Acrobat Reader 8, or Show Commenting Bar on the Mac). If these options are not available in your Adobe
Reader menus then it is possible that your Adobe version is lower than version 7 or the PDF has not been prepared
properly.
(PC, Acrobat 7)
(PC, Acrobat 8, right-click on title bar (Comment & Markup) to show additional icons)
(Mac)
RESPONDING TO THE AUTHOR QUERY FORM
Please check the Author Query Form and make any required responses in your annotations to the proof.
PLEASE DO NOT ATTEMPT TO EDIT THE TEXT ITSELF 
TO INDICATE INSERT, REPLACE, OR REMOVE TEXT
x Insert text
Click the ‘Text Edits’ button  on the Commenting Toolbar. Click to set the cursor location in the
text and simply start typing. The text will appear in a commenting box. You may also cut-and-paste text from
another file into the commenting box. Close the box by clicking on ‘x’ in the top right-hand corner. It can be
deleted by right clicking (for the PC, ctrl-click on the Mac) on it and selecting ‘Delete’.
x Replace text
Click the ‘Text Edits’ button  on the Commenting Toolbar. To highlight the text to be replaced,
click and drag the cursor over the text. Then simply type in the replacement text. The replacement text will appear
in a commenting box. You may also cut-and-paste text from another file into this box. To replace formatted text
(an equation for example) please Attach a file (see below).
x Remove text
Click the ‘Text Edits’ button  on the Commenting Toolbar. Click and drag over the text to be
deleted. Then press the delete button on your keyboard. The text to be deleted will then be struck through.
HIGHLIGHT TEXT / MAKE A COMMENT
Click on the ‘Highlight’ button  on the Commenting Toolbar. Click and drag over the text. To make a 
comment, double click on the highlighted text and simply start typing.
ATTACH A FILE
Click on the ‘Attach a File’ button  on the Commenting Toolbar. Click on the figure, table or formatted text to
be replaced. A window will automatically open allowing you to attach the file. To make a comment, go to ‘General’
and then ‘Description’ in the ‘Properties’ window. A graphic will appear indicating the insertion of a file.
LEAVE A NOTE / COMMENT
Click on the ‘Note Tool’ button  on the Commenting Toolbar. Click to set the location of the note on the
document and simply start typing. Do not use this feature to make text edits.
REVIEW
To review your changes, click on the ‘Show’ button  on the Commenting Toolbar. Choose ‘Show 
Comments List’. Navigate by clicking on a correction in the list. Alternatively, double click on any mark-up to open
the commenting box.
UNDO / DELETE CHANGE
To undo any changes made, use the right click button on your mouse (for PCs, Ctrl-Click for the Mac). Alternatively
click on ‘Edit’ in the main Adobe menu and then ‘Undo’. You can also delete edits using the right click (Ctrl-click on
the Mac) and selecting ‘Delete’.
SEND YOUR ANNOTATED PDF FILE BACK TO ELSEVIER
Save the annotations to your file and return as an e-mail attachment using the ‘reply’ button to the original mail. Do
NOT use the ‘Send comments’ feature of the Commenting Toolbar. Please ensure that all corrections are sent back to
us in one communication (including responses to the Author Query Form), as subsequent corrections will not be
possible.
Note: Comprehensive instructions are provided within your PDF file: to access these instructions please click on the
Comments and Markup menu in the main tool bar, or click on Help.
FURTHER POINTS
x Any (grey) halftones (photographs, micrographs, etc.) are best viewed on screen, for which they are optimized,
and your local printer may not be able to output the greys correctly.
x Colour artwork (if applicable): If you are unable to see any colour artwork, please check that the Display large
images tick box under File-->Preferences--> General... (or the Mac menu Adobe Reader/Preferences…) is ticked. 
x If the PDF files contain colour images, and if you do have a local colour printer available, then it will be likely
that you will not be able to correctly reproduce the colours on it, as local variations can occur.
x If you print the PDF file attached, and notice some ‘non-standard’ output, please check if the problem is also
present on screen. If the correct printer driver for your printer is not installed on your PC, the printed output will
be distorted.
d
r
r
t
c
p
t
t
d
g

f
n
k
A
p
i
O
a
m
s
h
t
o
e
o
T
p
a
h
n
m
t
s
a
s
t
p
r
i
h
p
t
b
t
r
w
p
J
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
AQ: 1
1
2
3
4
tapraid2/zl0-jcan/zl0-jcan/zl099908/zl02542d08z comp1 S1 11/30/09 Art: 1614Remifentanil Reduces the Release of Biochemical Markers of Myocardial
Damage After Coronary Artery Bypass Surgery. A Randomized Trial
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23Objective: Opioids, including remifentanil, have been
emonstrated to confer cardiac protection against ischemia
eperfusion injury in animals. This study evaluates whether
emifentanil preconditioning is protective in first time elec-
ive on pump coronary artery bypass surgery patients re-
eiving a standardized fentanyl (25 g/kg in total) and
ropofol anesthetic.
Design: A prospective, double blind, randomized, con-
rolled study.
Setting: University hospital; single institutional.
Participants: Forty patients scheduled for first time elec-
ive, on pump coronary artery bypass surgery for at least 3
iseased vessels.
Interventions: Patients randomized to the remifentanil
roup (n  20) received a 1 g/kg bolus followed by 0.5
g/kg/min infusion for 30 minutes after induction but be-
ore sternotomy, whilst the control group (n  20) received
ormal saline. Serial samples for measurement of creatine
inase (CKMB), cardiac troponin I (cTnI), ischemia modifiedass.
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lbumin (IMA) and heart type fatty acid binding protein
hFABP) were taken at baseline, pre bypass, T  10 minutes,
, 6, 12, and 24 hours after cross clamp release, to assess the
egree of myocardial damage.
Measurements and Main Results: Patients in the remifen-
anil group had lower levels of CKMB from T  2 hours to 24
ours, cTnI from T  10 minutes to T  12 hours, IMA from
 10 min to T  2 hours and h-FABP from T  10 minutes
o T  12 hours (p < 0.05). The time to tracheal extubation
as shorter in patients in the remifentanil group. The overall
ength of ICU and hospital stays was not different.
Conclusions: The addition of remifentanil to the anesthe-
ia regimen reduced the degree of myocardial damage. This
ncremental benefit may be attributable to either to remifen-
anil itself or to an overall increased opioid dose, the latter
ay be necessary to trigger cardiac protection.
2009 Elsevier Inc. All rights reserved.
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NUMBER OF TECHNIQUES and pharmacologic agents
have been evaluated for their ability to trigger cardiac
reconditioning in the perioperative setting. The most promis-
ng to date have been ischemia1 and volatile anesthetic agents.2
pioids have been demonstrated to provide cardiac protection
gainst ischemia reperfusion injury in a number of animal
odels3 with the delta opioid receptor (OR) the predominate
ubtype implicated in mediation.4 However, very few studies
ave examined the clinical potential for opioid cardioprotec-
ion. Myocytes have been shown to be sites of endogenous
pioid synthesis, storage and release5 and opioid levels are
levated during times of stress such as ischemia.6 Interestingly,
pioids also have an important role in mammalian hibernation.
his is a protective strategy to prolong survival of the brain and
eripheral organs since this energy-conserving state is associ-
ted with depletion of energy stores, intracellular acidosis and
ypoxia, similar to the conditions of ischemia. During hiber-
ation, circulating levels of opioid peptides are increased dra-
atically, and administration of opioid antagonists can effec-
ively reverse hibernation. Experimentally, opioids have been
hown to open the potassium ATP channels of mitochondria7
nd reduce the opening of the mitochondrial permeability tran-
ition pore,8 a putative end effector of cardioprotection.9
At present, neither the plasma concentration of opioids nor
he duration of exposure required to induce clinical cardiac
rotection have been defined. In addition, different opioid
eceptor subtype activation may confer different degrees of
schemic tolerance.10 Remifentanil, an ultra-short acting opioid,
as been shown to trigger both immediate and delayed cardiac
reconditioning in the rat heart.11,12 Although relatively selec-
ive for the  opioid receptor, its in vivo cardiac protection can
e blocked by antagonists of all three opioid receptor sub-
ypes.11 This study aimed to investigate whether the addition of
emifentanil to an otherwise standardized anesthetic technique
ould reduce myocardial damage from cardiopulmonary by-TE
D METHODSatient SelectionThis study protocol was approved by the Institutional Ethical Com-
ittee at the Sun Yat-Sen Cardiovascular Hospital, Shenzhen, China,
nd informed written consent was obtained from all study subjects.
atients scheduled for first time elective, on pump coronary artery
ypass surgery for at least 3 diseased vessels were recruited. Exclusion
riteria included patients with a Tu score of 9, concomitant valve
urgery, an ejection fraction of less than 30%, recent myocardial
nfarction (4 weeks), uncontrolled hypertension, congestive cardiac
ailure, atrioventricular or left bundle branch block, any hepatic, renal,
r pulmonary disease, any allergy to trial medications, body weight
100 kg or chronic opioid consumption. The Tu score is a 6-variable
isk index that derives a score based on age, sex, left ventricular
unction, type of surgery, urgency of surgery, and repeat operation.13 It
as been validated to predict mortality and length of ICU stay follow-
ng cardiac surgery.14,15 Patients’ medications were continued up to the
orning of surgery except for angiotensin converting enzyme inhibi-
ors. Antiplatelet therapy (including aspirin or nonsteroidal anti-inflam-
atory drugs) was stopped at least 1 week prior to surgery. Patients
ere allocated to either the remifentanil (group R) or control group
group C) by block randomization.
nesthesia and Surgery
All operations on study subjects were performed by the same sur-
eon, anesthesiologist, and perfusionist. The drug infusion was pre-
From the *Department of Anaesthesiology, University of Hong
ong, Hong Kong; and †Departments of Anesthesiology and ‡Cardio-
ascular Surgery, Sun Yat-Sen Cardiovascular Hospital, Shenzhen,
hina.
Address reprint requests to Michael G. Irwin, MD, FRCA, Depart-
ent of Anesthesiology, University of Hong Kong, Room 424, K Block,
ueen Mary Hospital, Pokfulam Road, Hong Kong. E-mail: mgirwin@
ku.hk
© 2009 Elsevier Inc. All rights reserved.
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ared by another anesthesiologist not involved with the case. The
atients’ anesthesiologist and intensive care unit (ICU) physicians were
linded to group allocation in this investigation. All clinical data were
ecorded by a clinical research assistant not involved with the clinical
are of the patient.
nesthesia
All patients received premedication with intramuscular morphine
0.1 mg/kg) and scopolamine (5 g/kg) 30 minutes before the opera-
ion. After admission to the operation theatre, oxygen was administered
ia a face mask at 5 L/min whilst intravenous and arterial line access
as established under local anesthesia. They were monitored with
-lead ECG, pulse oximetry, capnography, invasive arterial pressure,
nd pulmonary artery pressure during the operation. Anesthesia was
nduced with a titrated dose of etomidate until loss of eyelash reflex,
ollowed by a bolus of fentanyl (5 g/kg). Pancuronium (0.15 mg/kg)
as used for muscle relaxation and tracheal intubation was performed
minutes later. Anesthesia was maintained in both groups with an
nfusion of propofol (Diprivan; Astra Zeneca, Italy), which was com-
enced at a rate of 60 mcg/kg/min and titrated according to clinical
esponse. Patients in group R received a remifentanil bolus of 1 g/kg
ollowed by an infusion at a rate of 0.5 g/kg/min for 30 minutes. This
as predicted to produce a blood concentration of around 12 ng/mL.16
ive minutes before the end of the infusion, fentanyl was given in
ncrements to a total dose of 20 g/kg, prior to sternotomy. Patients in
he control group received 0.9% saline instead of remifentanil given at
he same infusion rate. The mean arterial pressure was maintained
ithin 20% of the pre operative value and above 60 mmHg. This was
chieved either with boluses of 0.5 g/kg phenylephrine to increase
rterial pressure or increasing the dose of propofol or the use of
lyceryl trinitrate to reduce arterial pressure. At the conclusion of the
peration, propofol sedation was continued in the intensive care unit.
emodynamic Monitoring
The right internal jugular vein and left radial artery were used for
emodynamic monitoring. Heart rate (HR), mean arterial pressure
MAP), pulmonary capillary wedge pressure (PCWP), central venous
ressure (CVP) , cardiac index (CI), systemic vascular resistance index
SVRI), and left ventricular stroke work index (LVSWI) were moni-
ored using a radial arterial catheter and Swan-Ganz catheter (Space
abs). Data were collected at baseline, preaortic cross clamp (ACC),
nd 10 minutes, 2, 6, 12, and 24 hours postaortic cross clamp release
ACCR), which was designated as T  0. In this study intraoperative
ypotension was defined as 30% less than that at baseline for a patient
ith hypertension, or a MAP below 60 mmHg.
ardiopulmonary Bypass
The Stockert-II heart-lung machine with roller pump and Affinity
embrane oxygenator (Medtronic) were used. The CPB circuit, the
xygenator, and the arterial filter (Xi Jing, Xian, China) were primed
ith 1500 mL of Ringer’s lactate containing 0.5 g/kg of mannitol and
000 IU of heparin. In both groups heparin was administered at a dose
f 3 mg/kg to achieve an activated clotting time (ACT) of 480 seconds
r greater before commencement of CPB. The nonpulsatile pump flows
ere adjusted to maintain a cardiac index between 2.4 L/min/m2 and
.6 L/min/m2. Anterograde intermittent administration of a cold car-
ioplegic solution, histidine-triptophan-ketoglutal (HTK; Custodial Dr.
oehler Chemie GMBH, Alsbach-Haenlein, Germany) was adminis-
ered both through the aortic root and through the graft after completion
f each distal anastomosis.
aboratory Assay
Blood samples were collected from each patient after measuring
emodynamic indices (see above). Samples were cooled to 4°C andTE
D 
PR
OO
F
entrifuged at 3000 rpm for 10 minutes at 4°C. Serum was stored at
70°C until assay. Serum levels of heart-type fatty acid-binding pro-
ein (h-FABP) were measured by enzyme-linked immunosorbent assay
IgCon Therapeutics Co. Ltd, Shanghai, China). Ischemia-modified
lbumin (IMA) levels were measured by the albumin cobalt binding
est on a Cobas Mira Plus analyzer (Roche). The albumin cobalt
inding method has been validated in previous studies.13,17 Free cobalt
an be measured with spectrophotometric methods and this indicates
he IMA level. The cutoff point of IMA for myocardial ischemia was
ccepted as 85 U/L according to the manufacturer’s recommenda-
ion.18,19 Levels of MB isoenzyme of creatine kinase (CK-MB) were
alculated using the photometric method (DiaSys Diagnostic System
mbH, Holzheim, Germany). Cardiac troponin I (cTnI) levels were
easured using immunometric technology (Chuanzhi Biomedical
roducts Corp., Taiyuan, China). The detection range for cTnI was
.1-50 ng/mL, and a cTnI value above 0.5 ng/mL was considered as
bnormal.
ELECTROCARDIOGRAPHIC CHANGES
A 12-lead electrocardiogram was recorded preoperatively
nd then daily postoperatively. The electrocardiographic diag-
osis criteria for perioperative myocardial infarction (PMI) was
or more of more of the following: new Q waves of more than
.04 seconds; a reduction in R waves of more than 25% in at
east 2 leads; significant ST segment deviation (elevation at the
point in 2 or more contiguous leads with cut-off point  0.2
V in leads V1, V2, or V3, and  0.1 mV in other leads) or T
ave abnormalities in 2 or more contiguous leads and new left
undle branch block. Intra-operative arrhythmia was consid-
red as 1 of the following: atrioventricular block, sustained
remature ventricular contractions, ventricular tachycardia, atrial
r ventricular fibrillation.
riteria for Inotrope Administration
Inotrope support was considered in the post bypass period if
or more of the following occurred: (1) mean arterial pressure
as less than 60 mmHg or decreased more than 20% from the
aseline value; (2) cardiac output index (CI) was less than 2.2
/min/m2 or (3) CVP or PCWP was more than 12 mmHg. For
he latter, nitroglycerin (1 to 10 g/kg/min) or sodium nitro-
russide (0.5 to 10 g/kg/min) was administered in addition to
notrope support. Dopamine was initially administered at a dose
f up to 5 g/kg/min. If there was no improvement, the dose of
opamine would then either be increased or changed to a
ombination of dobutamine (5 g/kg/min) plus epinephrine
tarting at 0.03 g/kg/min. An intra-aortic balloon pump was
onsidered if the epinephrine dose reached 0.1 g/kg/min. The
atient’s inotrope requirement was classified as none, mild
dopamine  5  g/kg/min) or moderate (dopamine  5
g/kg/min or dobutamine 5 g/kg/min or epinephrine  0.1
g/kg/min).
tatistical Analysis
Sample size was calculated using cardiac troponin levels as
he primary outcome. A minimum detected difference of 0.5
g/mL at T  6 between groups was considered significant. A
ample size of at least 14 was required to achieve a power of
.9 and a 2-sided  error of 0.05. Categorical variables are
resented by their number, summarized as a percentage and
ompared using 2 or Fisher’s exact test where appropriate.
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omparisons of continuous variables between groups were
nalyzed by unpaired t test. The time course of hemodynamic
ata was analyzed between groups by 2-way ANOVA for
epeated measurements. When a significant overall effect was
etected, Tukey’s honest significance difference test was per-
ormed to compare single mean values. Data for the biochem-
cal markers (CK-MB, cTnI, IMA, and h-FABP) were analyzed
or normality with the Kolmogorov-Smirnov test. Nonparamet-
ic data were compared at each time point using the Mann
hitney U test. Comparison of the areas under the curve for all
he markers was also made using unpaired t test. Differences
ere considered significant at a value of p  0.05. Statistical
nalyses were performed using the SPSS statistical software
ackage, version 13.0 (SPSS Inc., Chicago, IL).
RESULTS
Forty patients were recruited and randomized into either the
ontrol (n 20), or remifentanil group (n 20). There were no
ignificant differences in patient characteristics in terms of
emographics, medications, preexisting medical conditions,
aboratory results and cardiac function (Table 1). Surgical
evascularization was successfully achieved in all patients and
here were no differences in surgical and perfusion parameters
etween groups.
The results of the primary outcome of biochemical marker
elease are shown in Figure 1A to 1D. As the values for the
iochemical markers of myocardial ischemia and cellular dam-
ge did not have a Gaussian distribution, they were processed
n a nonparametric fashion. There were elevations in all tested
arkers after CPB when compared with baseline. They re-
urned to baseline values at T  6 for IMA and T  24 for
-FABP. The remifentanil group had lower levels of CK-MB at
 2, 6, 12, and 24 hours and lower cTnI at T  10 minutes,
, 6, and 12 hours. IMA levels were lower at T  10 minutes
nd 2 hours as were the h-FABP levels at these times as well as
t T  12 hours.
Although not powered for clinical outcome parameters, there
ere some trends noted between the 2 groups. These included
ignificantly more patients with episodes of arrhythmia in the
ontrol group. In addition there were more patients in the
ontrol group that required defibrillation to restore sinus
hythm after reperfusion (Table 2).
In the pre bypass period, patients in the remifentanil group
ad lower MAP as well as systemic vascular resistance index.
n the first 2 hours (T  2) following the release of the aortic
ross clamp (T  0) the remifentanil group had significantly
reater left ventricular stroke work index and cardiac index
Table 3). Post operatively there were fewer patients requiring
notrope support in the remifentanil group and, for those that
id, infusion rates were lower. One patient in the control group
eveloped a postoperative myocardial infarction that later re-
uired IABP support. More patients had ECG changes postop-
ratively in the control group. The time to tracheal extubation
as shorter in patients in the remifentanil group. However, the
verall length of ICU and hospital stays was not different
etween the 2 groups and there were no deaths in any of the
atients in the study (Table 4).TE
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DISCUSSION
Results from this study suggest that a short period of high
ose remifentanil before cardiopulmonary bypass confers a
reconditioning effect over and above that provided by fenta-
yl. From laboratory data, there was an increase in infarct
paring effect with increasing dose of remifentanil.11 Clinically,
lood concentrations of 4-8 ng/mL produce little further reduc-
ion in the minimal alveolar concentration of isoflurane (a
easure of opioid potency)20 and a blood concentration of 7.5
g/mL depresses the epinephrine response to pneumoperito-
eum and surgery.21 An infusion regime was, therefore, chosen
hat would produce blood concentrations of around 12 ng/mL
hich is a dose sufficiently high to reduce the stress response
f surgery. The 30-minute infusion period was chosen as lab-
ratory data showed that three 5 minute infusions of remifen-
anil interspersed with 5-minute infusion free periods (a total of
0 minutes) was sufficient to demonstrate a preconditioning
esponse in our animal studies. A decision was made not to
Table 1. Preoperative Patient Data
Variables Group C (n  20) Group R (n  20)
Demographics
Age (y) 65.6  3 64.50  2
Sex (M/F) 15/5 14/6
Weight (kg) 69.50  10.2 68.10  7.6
BSA (m2) 1.69  0.41 1.72  0.34
Preoperative medications
 blockers 14 13
Calcium blockers 7 8
ACE inhibitors 8 9
Nitrates 16 17
Diuretics 5 5
Sulfonylurea 4 3
Insulin 6 5
Aspirin 14 15
Other diseases
Diabetes 7 6
Hypertension 7 8
COPD 3 2
Peripheral Vascular Disease 2 1
Tu Score 3.14  0.4 3.05  0.3
Laboratory test
Hemoglobin (g/L) 125.5  23.2 123.7  11.6
Platelet count (109/L) 215.5  36.7 224.2  48.5
ALT 20.1  7.5 18.7  3.1
AST 31.2  10.3 30.6  12.3
Albumin (g/L) 42.2  7.5 41.1  3.1
Urea (mol/L) 233.2  57.3 219.6  48.2
Creatinine (mol/L) 120.3  36.5 104.3  20.1
Cardiac status
Previous MI (4 weeks) 8 9
LVEF 30%-49%, 4 5
LVEF  49%, 16 15
LMCA stenosis  50% 14 15
NOTE. Data are presented as mean  SD or number (n).
Abbreviations: BSA, body surface area; ACE, angiotensin-convert-
ng enzyme; COPD, chronic obstructive pulmonary disease; ALT, ala-
ine aminotransferase; AST, aspartate aminotransferase; MI, myocar-
ial infarction; LVEF, left ventricular ejection fraction; LMCA, left main
oronary artery; NS, not significant.
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ulse the delivery of remifentanil to avoid hemodynamic insta-
ility that such a regime may introduce. Once triggered, a
reconditioning response should have a protective window of
everal hours and the concentrations of remifentanil should
ave dissipated by the time of cross clamping.
A number of agents including those used in the perioperative
eriod have been demonstrated to protect the myocardium. This
tudy attempted to minimize the use of such agents as they
ould have acted as confounders, and other drug use was the
ame in both groups. Propofol was used rather than a volatile
nesthetic as certain volatile agents have been shown to confer
cute preconditioning.22,23 Propofol too has been shown in 1
tudy to protect the heart during bypass surgery, probably via
ts antioxidant properties.24 During the remifentanil infusion
eriod, the control group may have temporarily received a
igher dose of propofol than the remifentanil group, which may
otentially reduce the differences between groups. However,
Fig 1. Blood levels of biochemical markers over time. Values are p
ortic cross clamp was applied; ACCR, aortic cross clamp release. pTE
D 
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F
he dose used in the control would have been less than that
hown to be cardioprotective. As it would be unethical to
xclude the use of opioids in cardiac surgical patients, the same
ose of fentanyl was used in both groups to equalize the effect
his opioid may have had on outcome. Any difference in
otency between fentanyl and remifentanil should, therefore,
ot affect the outcome. In addition to the conventional markers
f cardiac damage after cardiopulmonary bypass (CKMB and
ardiac troponin I)25, we also employed 2 innovative markers
hat are not routinely used. Ischemia modified albumin (IMA)
s a metabolic variant of albumin that may represent an innate,
ndogenous response to ischemia.26 In addition to myocardial
schemia,18,27 its level is increased in acute stroke28, skeletal
uscle ischemia29 and pulmonary embolism.30 It has reduced
inding capacity to transition metals such as cobalt, copper or
ickel and this property is exploited during laboratory measure-
ents. It has rapid kinetics, rising within 30 minutes and
as median (error bars interquartile range). Pre-ACC, period before
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eturning to baseline within 12 hours after percutaneous angio-
lasty procedures.18 Heart type fatty acid binding protein
hFABP) is a small water soluble intracellular protein that
esides in the cytoplasm.31 Due to its small size, it is rapidly
eleased into the bloodstream following sarcolemmal damage.32
t has been shown to peak as early as 60 minutes after reper-
usion following cardiopulmonary bypass, much earlier than
KMB and troponin.33,34
As opioids were used in both groups, interpretation of these
esults must be tempered with caution as it may be accounted
Table 2. Int
Variable
Pre bypass fluids (mL)
Patients requiring phenylephrine pre bypass (n)
Post bypass fluids (mL)
HTK (mL)
Aortic cross-clamping time (min)
Aortic side-clamping (min)
CPB time (min)
Operation time (min)
Number of grafts
Number of patients requiring cardioversion to
restore rhythm after CPB (n)
Dopamine time (min)
Dopamine average dose (g/kg/min)
Phenylephrine (mg)
Propofol (mg)
Fentanyl (g)
Post bypass adverse events
Bradycardia (n)
Hypotension (n)
Arrhythmias (n)
NOTE. Data are presented as mean  SD or number (n).
Abbreviations: Arrhythmia, atrioventricular block, sustained prema
brillation occurring after separation from cardiopulmonary bypass
ardioplegia solution; CPB, cardiopulmonary bypass.
Table 3. Patients’ Perio
Variable Group Baseline Pre-AC
HR (beats/min) C 72  14 75 
R 74  20 76 
MAP (mmHg) C 94  14 88 
R 90  18 70 
CVP (mmHg) C 8  1 8 
R 8  2 8 
PCWP (mmHg) C 8  1 8 
R 8  1 7 
CI (L/min/m2) C 1.9  0.1 1.9 
R 1.8  0.2 2.7 
SVRI (dynes  s  cm5/m2) C 2984  526 2606 
R 2738  369 1872 
LVSWI (g  m/m2) C 25.5  9 30.5 
R 28.3  22 31.3 
NOTE. Data are presented as mean  SD.
Abbreviations: #, difference between control and remifentanil g
ross-clamping; ACCR, aortic cross clamp release; HR, heart rate; MAP
apillary wedge pressure; CI, cardiac index; SVRI, systemic vascular resistTE
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or by a number of possible explanations. First, there could be
difference in cardioprotective properties between remifentanil
nd fentanyl due to a different affinity for opioid receptor
ubtypes, as all other anesthetic and surgical factors were
imilar in both groups except for the use of remifentanil. We
eel that this is an unlikely explanation. Remifentanil is chem-
cally related to fentanyl and both are predominantly  opioid
eceptor agonists.35 Remifentanil also has some action on delta
nd, to a lesser extent, kappa opioid receptors.36 The cardiac
reconditioning effect of remifentanil in vivo can be blocked
rative Data
p C (n  20) Group R (n  20) p Value
4  138 869  142 0.73
10 17 0.02
7  372 1294  331 0.75
1  248 1715  269 0.14
8  12 75  8 0.38
1  13 39  5 0.59
2  28 147  34 0.59
8  35 236  33 0.27
.2  0.7 3.1  0.5 0.61
8 2 0.03
6  20 48  17 0.17
1  0.57 2.78  1.61 0.06
1  0.06 0.23  0.09 0.41
0  203 1204  251 0.25
5  0.2 1.7  0.2 0.43
4 5 1.0
5 6 1.0
8 2 0.03
ventricular contractions, ventricular tachycardia, atrial or ventricular
efore arrival in ICU. HTK, histidine-triptophan-ketoglutala, a type of
ve Hemodynamic Data
Post-ACCR
10 min 2 hours 6 hours 12 hours 24 hours
68.2  11 82  14 85  20 79  10 83  8
70.6  20 88  25 83  23 80  16 88.  11
64  15 83  13 88  10 85  20.3 88  17
71  22 86  17 88  12 83  18 90  18
9  2 9  2 9  1 10  1 11  3
9  2 9  2 9.  1 10  1 11  4
7  1 8  1 9  1 10  1 12  4
7  1 8  1 9  1 10  1 12  3
2.0  0.3 2.2  0.3 2.5  0.6 2.6  0.3 2.4  0.3
2.3  0.3 2.5  0.13# 2.5  0.3 2.5  0.4 2.5  0.2
2448  371 2506  417 2671  315 2318  329 2571  344
2287  318 2482  339 2581  403 2481  278 2392  276
34.1  12.3 37.6  9.1 38.5  7.4 37.3  9.3 38.5  12.7
43.3  8.# 48.2  10.2# 43.3  11.5 41.4  8.5 40.3  10.4
(p  0.05); C, control group; R, remifentanil group; ACC, aortic
n arterial pressure; CVP, central venous pressure; PCWP, pulmonaryraope
Grou
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y  and  as well as mu receptor antagonists.11,37 However,
his observation may also be a result of functional interaction or
cross talk” between different opioid receptor subtypes,38,39
hereby activation or blockade of 1 subtype could possibly
nfluence other subtypes. Fentanyl can also protect the heart in
itro via the delta receptor.40 However, there is little data
irectly comparing the opioid receptor subtype affinity in car-
iac tissue between fentanyl and remifentanil.
It is more likely that the results are simply a function of the
ifference in the total dose of opioid given. The potency of
emifentanil is similar to fentanyl.41 A higher plasma concen-
ration of total opioid in the remifentanil group may have had
more powerful agonist effect on the appropriate receptors on
greater number of cells in a heart with diseased vessels. This
ould have clinical implications for patients undergoing on
ump cardiac surgery. High doses of opioids were commonly
sed for cardiac anesthesia in the past42 but have now been
ubstantially reduced, commensurate with the trend towards
ast track surgery. Remifentanil, however, has unique pharma-
okinetic properties that allow rapid onset of high target opioid
oncentrations intraoperatively with very rapid recovery on
essation of infusion avoiding the usual consequence of pro-
onged respiratory depression.41,43 Studies comparing the use of
emifentanil versus fentanyl in this setting have concluded that
emifentanil is safe and suitable for fast track surgery.44,45
Table 4. Postoperative Data
Variable
Group C
(n  20)
Group R
(n  20) p Value
Inotrope use
None (n) 3 8 0.07
Mild (n) 11 12 1.0
Moderate (n) 6 0 0.02
Postoperative MI (n) 1 0 1.0
ST-segment deviations (n) 7 3 0.14
New path. Q-waves, (n) 4 1 0.34
Requirement for IABP (n) 1 0 1.0
Tracheal extubation (hours) 15  3 13  3 0.04
ICU stay (hours) 38  9 36  11 0.39
Hospital stay (days) 13  4 11  3 0.1
Death in hospital (n) 0 0 1.0
NOTE. Data are presented as mean  SD or number (n). Inotrope
se, mild  dopamine  5 g/kg/min; moderate  dopamine/dobut-
mine  5 g/kg/min or epinephrine  0.1 g/kg/min.
Abbreviations: MI, myocardial infarction; IABP, intra-aortic balloon
ump; ICU, intensive care unit.N REFEREN
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urthermore in these studies, there were indications that higher
pioid doses may be beneficial. There were fewer patients
uffering myocardial infarction in the remifentanil and high
ose fentanyl group compared with a low dose fentanyl group
n the study by Myles and colleagues.45 In 2 other studies there
as also a trend towards lower CKMB levels in the remifen-
anil group in 144 and statistically lower CKMB and a trend
owards lower troponin T levels in the other.46 However, in the
atter 2 studies volatile anesthetic agents were also used and
hat may have influenced the results.
There are several limitations to this study. This was a small
tudy that was not statistically powered to judge certain clinical
utcomes such as the incidence of death or myocardial infarc-
ion. As mentioned, it was not possible to avoid the use of
pioids in the control group as this is standard practice in
ardiac anesthesia and, therefore, fentanyl was used. It follows
hat any anticipated difference between the 2 groups would be
mall and hence our choice of 0.5 ng/mL as a significant
ifference when calculating the study power. Plasma drug
oncentrations were not measured and, since only a single dose
as used, there is no dose response data. The results do suggest
hat either remifentanil or an increased overall opioid dose is
eneficial but the question of whether 1 opioid is superior to
nother remains unanswered.
Oxidative stress as a result of reperfusion injury is a known
ausative factor of cardiac muscle injury and may occur after
ardiac bypass.47 Myocardial reperfusion injury is also seen
fter the use of primary percutaneous coronary intervention
ollowing myocardial infarction where it has been suggested
hat this may account for significant morbidity and up to 50%
f the final size of the infarct.48,49 Pharmacologic attempts to
arget known mediators of this process have generally been
neffective, although, recently, cyclosporine administered im-
ediately before primary PCI significantly reduced the release
f CK, cTnI and infarct size.50 Perhaps remifentanil may be
orthy of further study in this setting.
In conclusion, the results from this study demonstrate that
he addition of high doses of remifentanil prior to sternotomy,
educed cardiac injury during on pump coronary artery bypass
urgery as manifest by a reduction in the release of a range of
iochemical markers. High dose opioids, particularly in con-
unction with the pharmacokinetics of remifentanil, may rep-
esent a clinically simple and safe technique for cardiac pre-
onditioning. 343
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